Skip to content
PICO Portalanswers from OpenAlex

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis

PaperCitations, authors & open-access status

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis is a paper indexed in PICO Portal from OpenAlex.

How many citations does Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis have?

PICO Portalcitation count

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis has 350 citations in the OpenAlex counts PICO Portal stores.

When was Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis published?

PICO Portalyear

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis has 2010 year in the PICO Portal index.

What is the open-access status of Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis?

PICO Portaloa status

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis has bronze oa status in the PICO Portal index.

What is the DOI of Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis?

PICO Portaldoi

The DOI for Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis is on the source record.

What is the PMID of Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis?

PICO Portalpmid

The PMID for Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis is on the source record.

What is the OpenAlex record for Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis?

PICO Portalopenalex

The OpenAlex for Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial